ADV-tk重組腺病毒的構建及檢測_《中國普外基礎與臨床雜志》

作者：

陳耿臻 , 韓慧 , 許銘炎 , 鄧小玲

汕頭大學醫學院第二附屬醫院外三科（廣東汕頭 515041）;

關鍵詞：

基因治療自殺基因胸苷激酶基因腺病毒載體

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的應用基因重組技術，構建含胸苷激酶（tk）自殺基因的復制缺陷型腺病毒（ADV-tk），為進一步研究tk自殺基因對腫瘤的抑制作用奠定基礎。
方法采用細胞內同源重組法構建攜帶tk基因的ADV-tk，經PCR鑒定正確后進行擴增、純化和滴度測定。重組腺病毒ADV-tk體外轉染人肝癌SMMC-7721細胞，RT-PCR檢測tk基因的整合和表達。建立裸鼠人肝癌動物模型，腹腔注射ADV-tk，熒光顯微技術觀察ADV-tk基因在肝臟的轉染情況和對腫瘤細胞的抑制作用。
結果構建的重組腺病毒中帶有tk基因，經擴增、純化后測得重組腺病毒滴度為1.4×1010 pfu/ml。ADV-tk體外轉染SMMC-7721細胞后，RT-PCR檢測顯示tk基因在細胞中整合并且有效表達。體內檢測結果發現ADV-tk在肝臟有明顯轉染，腫瘤組織中凋亡細胞明顯增多。
結論本研究構建的攜帶tk基因的復制缺陷型腺病毒獲得成功，可用于下一步研究。

引用本文： 陳耿臻,韓慧,許銘炎,鄧小玲. ADV-tk重組腺病毒的構建及檢測. 中國普外基礎與臨床雜志, 2010, 17(7): 703-706. doi: 復制

1.	Vassaux G, MartinDuque P. Use of suicide genes for cancer gene therapy: study of the different approaches [J]. Expert Opin Biol Ther, 2004; 4(4): 519530.
2.	Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy [J]. Mol Aspects Med, 2007; 28(1): 441.
3.	Altaner C. Prodrug cancer gene therapy [J]. Cancer Lett, 2008; 270(2): 191201.
4.	Si S, Sun Y, Li Z, et al. Gene therapy by membraneexpressed superantigen for αfetoproteinproducing hepatocellular carcinoma [J]. Gene Ther, 2006; 13(22): 16031610.
5.	Stefani AL, Barzon L, Castagliuolo I, et al. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma [J]. Hepatol, 2005; 42(5): 728735.
6.	Song TJ, Eisenberg DP, Adusumilli PS, et al. Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines [J]. J Gastrointest Surg, 2006; 10(4): 532542.
7.	Cai X, Zhou J, Chang Y, et al. Targeting gene therapy for hepatocarcinoma cells with the E.coli purine nucleoside phosphorylase suicide gene system directed by a chimeric αfetoprotein promoter [J]. Cancer Lett, 2008; 264(1): 7182.
8.	Li YM, Song ST, Jiang ZF, et al. Telomerasespecific oncolytic virotherapy for human hepatocellular carcinoma [J]. World J Gastroenterol, 2008; 14(8): 12741279.
9.	Zhou J, Gao Q, Chen G, et al. Novel oncolytic adenovirus selectively targets tumorassociated pololike kinase 1 and tumor cell viability [J]. Clin Cancer Res, 2005; 11(23): 84318440.
10.	Majumdar AS, Hughes DE, Lichtsteiner SP, et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters [J]. Gene Ther, 2001; 8(7): 568578.
11.	Aguilar LK, The BS, Vaachaki MT, et al. AdVtk/valacyclovir gene therapy in combination with radiotherapy for prostate cancer: interim results of a phase Ⅰ/Ⅱ clinical trial [C]. Proc Am Soc Clin Oncol, 21: 2002 (abstr 25).
12.	Ling CQ, Li B, Zhang C, et al. Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma [J]. Ann Oncol, 2005; 16(1): 109115.
13.	Gentry BG, Boucher PD, Shewach DS. Hydroxyurea induces bystander cytotoxicity in cocultures of herpes simplex virus thymidine kinaseexpressing and nonexpressing HeLa cells incubated with ganciclovir [J]. Cancer Res, 2006; 66(7): 38453851.
14.	Li N, Zhou J, Weng D, et al. Adjuvant adenovirusmediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma [J]. Clin Cancer Res, 2007; 13(19): 58475854.
15.	Palmer DH, Mautner V, Mirza D, et al. Virusdirected enzyme prodrug therapy: intratumoral administration of a replicationdeficient adenovirus encoding nitroreductase to patients with resectable liver cancer [J]. J Clin Oncol, 2004; 22(9): 15461552.
16.	van Dillen IJ, Mulder NH, Vaalburg W, et al. Influence of the bystander effect on HSVtk/GCV gene therapy. A review [J]. Curr Gene Ther, 2002; 2(3): 307322.
17.	Unger MM, Wahl J, Ushmorov A, et al. Enriching suicide gene bearing tumor cells for an increased bystander effect [J]. Cancer Gene Ther, 2007; 14(1): 3038.
18.	Zhang Q, Chen G, Peng L, et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dualregulated oncolytic adenovirus [J]. Clin Cancer Res, 2006; 12(21): 65236531.
19.	Hsieh JL, Lee CH, Teo ML, et al. Transthyretindriven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma [J]. Cancer Sci, 2009; 100(3): 537545.
20.	Li G, Sham J, Yang J, et al. Potent antitumor efficacy of an E1B 55kDadeficient adenovirus carrying murine endostatin in hepatocellular carcinoma [J]. Int J Cancer, 2005; 113(4): 640648.
21.	He LF, Gu JF, Tang WH, et al. Significant antitumor activity of oncolytic adenovirus expressing human interferonβ for hepatocellular carcinoma [J]. J Gene Med, 2008; 10(9): 983992.
22.	Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adenoassociated virus (AAV) as novel vectors for human gene therapy [J]. Curr Gene Ther, 2003; 3(4): 281304.
23.	Coura Rdos S, Nardi NB. The state of the art of adenoassociated virusbased vectors in gene therapy [J]. Virol J, 2007; 4: 99105.
24.	Liu H, Peng CH, Liu YB, et al. Inhibitory effect of adenoassociated virusmediated gene transfer of human endostatin on hepatocellular carcinoma [J]. World J Gastroenterol, 2005; 11(22): 33313334.
25.	Blechacz B, Splinter PL, Greiner S, et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma [J]. Hepatology, 2006; 44(6): 14651477.
26.	劉自明, 嚴律南, 李馨筱. 包載攜有HSVTK基因腺病毒PLG微球的制備 [J]. 中國普外基礎與臨床雜志, 2007; 14(4): 399402.
27.	羅濤, 張強, 張建, 等. 腺病毒介導胸苷激酶基因對靜脈平滑肌細胞增殖及內膜增生抑制作用的研究 [J]. 中國普外基礎與臨床雜志, 2006; 13(3): 291294.
28.	李梅生, 梁力建, 黃潔夫, 等. HSVtk/CD融合基因殺傷人膽管癌細胞QBC939的體內實驗 [J]. 中國普外基礎與臨床雜志, 2005; 12(6): 581584.

1. Vassaux G, MartinDuque P. Use of suicide genes for cancer gene therapy: study of the different approaches [J]. Expert Opin Biol Ther, 2004; 4(4): 519530.
2. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy [J]. Mol Aspects Med, 2007; 28(1): 441.
3. Altaner C. Prodrug cancer gene therapy [J]. Cancer Lett, 2008; 270(2): 191201.
4. Si S, Sun Y, Li Z, et al. Gene therapy by membraneexpressed superantigen for αfetoproteinproducing hepatocellular carcinoma [J]. Gene Ther, 2006; 13(22): 16031610.
5. Stefani AL, Barzon L, Castagliuolo I, et al. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma [J]. Hepatol, 2005; 42(5): 728735.
6. Song TJ, Eisenberg DP, Adusumilli PS, et al. Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines [J]. J Gastrointest Surg, 2006; 10(4): 532542.
7. Cai X, Zhou J, Chang Y, et al. Targeting gene therapy for hepatocarcinoma cells with the E.coli purine nucleoside phosphorylase suicide gene system directed by a chimeric αfetoprotein promoter [J]. Cancer Lett, 2008; 264(1): 7182.
8. Li YM, Song ST, Jiang ZF, et al. Telomerasespecific oncolytic virotherapy for human hepatocellular carcinoma [J]. World J Gastroenterol, 2008; 14(8): 12741279.
9. Zhou J, Gao Q, Chen G, et al. Novel oncolytic adenovirus selectively targets tumorassociated pololike kinase 1 and tumor cell viability [J]. Clin Cancer Res, 2005; 11(23): 84318440.
10. Majumdar AS, Hughes DE, Lichtsteiner SP, et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters [J]. Gene Ther, 2001; 8(7): 568578.
11. Aguilar LK, The BS, Vaachaki MT, et al. AdVtk/valacyclovir gene therapy in combination with radiotherapy for prostate cancer: interim results of a phase Ⅰ/Ⅱ clinical trial [C]. Proc Am Soc Clin Oncol, 21: 2002 (abstr 25).
12. Ling CQ, Li B, Zhang C, et al. Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma [J]. Ann Oncol, 2005; 16(1): 109115.
13. Gentry BG, Boucher PD, Shewach DS. Hydroxyurea induces bystander cytotoxicity in cocultures of herpes simplex virus thymidine kinaseexpressing and nonexpressing HeLa cells incubated with ganciclovir [J]. Cancer Res, 2006; 66(7): 38453851.
14. Li N, Zhou J, Weng D, et al. Adjuvant adenovirusmediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma [J]. Clin Cancer Res, 2007; 13(19): 58475854.
15. Palmer DH, Mautner V, Mirza D, et al. Virusdirected enzyme prodrug therapy: intratumoral administration of a replicationdeficient adenovirus encoding nitroreductase to patients with resectable liver cancer [J]. J Clin Oncol, 2004; 22(9): 15461552.
16. van Dillen IJ, Mulder NH, Vaalburg W, et al. Influence of the bystander effect on HSVtk/GCV gene therapy. A review [J]. Curr Gene Ther, 2002; 2(3): 307322.
17. Unger MM, Wahl J, Ushmorov A, et al. Enriching suicide gene bearing tumor cells for an increased bystander effect [J]. Cancer Gene Ther, 2007; 14(1): 3038.
18. Zhang Q, Chen G, Peng L, et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dualregulated oncolytic adenovirus [J]. Clin Cancer Res, 2006; 12(21): 65236531.
19. Hsieh JL, Lee CH, Teo ML, et al. Transthyretindriven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma [J]. Cancer Sci, 2009; 100(3): 537545.
20. Li G, Sham J, Yang J, et al. Potent antitumor efficacy of an E1B 55kDadeficient adenovirus carrying murine endostatin in hepatocellular carcinoma [J]. Int J Cancer, 2005; 113(4): 640648.
21. He LF, Gu JF, Tang WH, et al. Significant antitumor activity of oncolytic adenovirus expressing human interferonβ for hepatocellular carcinoma [J]. J Gene Med, 2008; 10(9): 983992.
22. Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adenoassociated virus (AAV) as novel vectors for human gene therapy [J]. Curr Gene Ther, 2003; 3(4): 281304.
23. Coura Rdos S, Nardi NB. The state of the art of adenoassociated virusbased vectors in gene therapy [J]. Virol J, 2007; 4: 99105.
24. Liu H, Peng CH, Liu YB, et al. Inhibitory effect of adenoassociated virusmediated gene transfer of human endostatin on hepatocellular carcinoma [J]. World J Gastroenterol, 2005; 11(22): 33313334.
25. Blechacz B, Splinter PL, Greiner S, et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma [J]. Hepatology, 2006; 44(6): 14651477.
26. 劉自明, 嚴律南, 李馨筱. 包載攜有HSVTK基因腺病毒PLG微球的制備 [J]. 中國普外基礎與臨床雜志, 2007; 14(4): 399402.
27. 羅濤, 張強, 張建, 等. 腺病毒介導胸苷激酶基因對靜脈平滑肌細胞增殖及內膜增生抑制作用的研究 [J]. 中國普外基礎與臨床雜志, 2006; 13(3): 291294.
28. 李梅生, 梁力建, 黃潔夫, 等. HSVtk/CD融合基因殺傷人膽管癌細胞QBC939的體內實驗 [J]. 中國普外基礎與臨床雜志, 2005; 12(6): 581584.

《中國普外基礎與臨床雜志》

ADV-tk重組腺病毒的構建及檢測

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

ADV-tk重組腺病毒的構建及檢測

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料